Top Markets
Coin of the day
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.

INTI
Rang in Aktien #30834
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida,... Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Aktienkurs
$0.089
Zuletzt synchronisiert: 2026-08-17
Marktkapitalisierung
$15.36M
Veränderung (1 Tag)
50.59%
Veränderung (1 Jahr)
72.65%
Land
US
Handel Inhibitor Therapeutics, Inc. (INTI)

Kategorie

EPS für Inhibitor Therapeutics, Inc. (INTI)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Inhibitor Therapeutics, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Inhibitor Therapeutics, Inc. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
$17.32 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH
$13.70 -
BE